LOUISVILLE, Ky. / Aug 17, 2023 / Business Wire / Humana (NYSE: HUM) announced sixteen community-based organizations across the nation will receive grants totaling over $121,500. With millions of medical and specialty care members across the nation, the healthcare company is taking intentional action toward a more equitable, accessible and affordable healthcare ecosystem.
“Humana is committed to supporting organizations in our communities that are tackling health inequities every day,” said J. Nwando Olayiwola, MD, MPH, Chief Health Equity Officer and Senior Vice President for Humana. “This support will help remove existing barriers and strengthen those leading important work in communities we serve.”
Humana has organized its health equity strategy into three core areas:
Recipients were selected from applicants within Humana national partner communities and chosen based on alignment with the above core areas, health equity-related programming, and ability to demonstrate a commitment to long-term solutions. Allocations ranged from $500 - $9,000. The following organizations received grant funding:
“The inaugural 2023 spring/fall health equity grant cycles were launched to support initiatives and/or organizations within Humana’s footprint, deepen the organization’s impact in advancing health equity and address social needs within communities,” said Lisa Porter, MPH, CHES, Director of Community Engagement at Humana. A second round of awards will be selected and awarded this fall.
Explore how Humana is intentionally advancing health equity in Humana’s 2023 Health Equity Issue Brief and 2022 Impact Report.
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
| Last Trade: | US$260.28 |
| Daily Volume: | 0 |
| Market Cap: | US$31.300B |
December 16, 2025 November 05, 2025 October 20, 2025 August 27, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load